Neurology Minute

Dr. Tesha Monteith discusses growing evidence supporting CGRP-targeted therapies as first-line preventive treatment options for people with migraine.
Show citation: 
Reuter U, Dycke AV, Versijpt J, et al. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. Lancet Neurol. 2026;25(9):806-817. doi:10.1016/S1474-4422(26)00214-0

Dr. Casey Kozak discusses why most patients referred with seronegative NMOSD ultimately receive alternative diagnoses, underscoring the challenges of accurate diagnosis in antibody-negative cases. 
Show citation:
Lang MV, Welk GM, Tajfirouz DA, et al. Unveiling Misdiagnosis: Rethinking Seronegative NMOSD. Mult Scler. 2025;31(11):1381-1384. doi:10.1177/13524585251360648

Dr. Katie Krulisky and Dr. Kelsey Smith discuss the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife.
Show citation: 
Smith KM, Faubion SS, Vadlamudi L, et al. The Menopause Transition and Epilepsy: A Focus on Therapeutics. Neurol Clin Pract. 2026;16(5):e200650. doi:10.1212/CPJ.0000000000200650

Dr. Katie Krulisky and Dr. Kelsey Smith discuss the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife.
Show citation: 
Smith KM, Faubion SS, Vadlamudi L, et al. The Menopause Transition and Epilepsy: A Focus on Therapeutics. Neurol Clin Pract. 2026;16(5):e200650. doi:10.1212/CPJ.0000000000200650

Dr. Casey Kozak discusses a new scoring system for MOGAD identification. 
Show citation:
Vilaseca A, Filippatou AG, Said Y, et al. TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-IgG Test Results. Neurol Neuroimmunol Neuroinflamm. 2026;13(5):e200617. doi:10.1212/NXI.0000000000200617